We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

14 hedge funds and large institutions have $651K invested in Lexaria Bioscience in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.38% less ownership

Funds ownership: 11.41% → 11.03% (-0.38%)

18% less funds holding

Funds holding: 17 → 14 (-3)

65% less capital invested

Capital invested by funds: $1.85M → $651K (-$1.2M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ICM
Invenomic Capital Management
Massachusetts
+$380K
2
TRCT
Tower Research Capital (TRC)
New York
+$8.89K
3
Wells Fargo
Wells Fargo
California
+$3

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$67.4K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$41.5K
3
CC
Centiva Capital
New York
-$32.8K
4
UBS Group
UBS Group
Switzerland
-$5.88K
5
Renaissance Technologies
Renaissance Technologies
New York
-$3.76K
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
1
Invenomic Capital Management
Massachusetts
$560K +$380K +293,470 +62%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$35.3K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$24.3K – – –
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$11.2K -$67.4K -52,026 -77%
Renaissance Technologies
5
Renaissance Technologies
New York
$8K -$3.76K -2,900 -21%
TRCT
6
Tower Research Capital (TRC)
New York
$7.99K +$8.89K +6,862 +168%
1832 Asset Management
7
1832 Asset Management
Ontario, Canada
$1.96K – – –
Osaic Holdings
8
Osaic Holdings
Arizona
$1.49K – – –
Wells Fargo
9
Wells Fargo
California
$782 +$3 +2 +0.2%
APC
10
Aspire Private Capital
North Carolina
$292 – – –
FFA
11
Farther Finance Advisors
California
$121 – – –
UBS Group
12
UBS Group
Switzerland
$72 -$5.88K -4,540 -98%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
– -$41.5K -15,268 Closed
CC
14
Centiva Capital
New York
– -$32.8K -12,059 Closed
GCM
15
Gables Capital Management
Florida
– -$35 -13 Closed

LEXX Hedge Fund Activity: Q2 2023 in Review

14 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q2 2023, worth a combined $651K — down 65% from $1.85M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of LEXX and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was Invenomic Capital Management, adding an estimated $380K. The largest seller was Susquehanna International Group, cutting an estimated $67.4K.

  • 14 institutional investors held Lexaria Bioscience (LEXX) as of Q2 2023, down from 17 in Q1 2023.
  • Funds reported $651K of Lexaria Bioscience stock for Q2 2023, down 65% quarter-over-quarter.
  • 0 funds opened new Lexaria Bioscience positions in Q2 2023 and 3 closed out, a net change of -3 holders.
  • The largest Lexaria Bioscience buyer in Q2 2023 was Invenomic Capital Management, an estimated $380K added.
  • The largest Lexaria Bioscience seller in Q2 2023 was Susquehanna International Group, an estimated $67.4K sold.

Based on aggregated 13F filings for Q2 2023.